Susan P Whitman

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43240, USA
    Blood 111:1552-9. 2008
  2. pmc Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Blood 109:5164-7. 2007
  3. pmc RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures
    Jason H Mendler
    The Ohio State University, Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 30:3109-18. 2012
  4. pmc BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Sebastian Schwind
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 116:5660-9. 2010
  5. pmc Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 116:788-92. 2010
  6. pmc Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:5078-87. 2008
  7. ncbi request reprint High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3337-43. 2007
  8. doi request reprint MicroRNA expression in cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 358:1919-28. 2008
  9. pmc IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:2348-55. 2010
  10. pmc Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:4595-602. 2008

Research Grants

  1. FLT3 GENOTYPES IN ACUTE MYELOID LEUKEMIA
    Susan Whitman; Fiscal Year: 2006

Detail Information

Publications42

  1. pmc FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43240, USA
    Blood 111:1552-9. 2008
    ....
  2. pmc Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Blood 109:5164-7. 2007
    ..5-7.7 years). Intensive consolidation therapy that included autologous peripheral stem-cell transplantation during CR1 may have contributed to the better outcome of this historically poor-prognosis group of CN-AML patients with MLL-PTD...
  3. pmc RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures
    Jason H Mendler
    The Ohio State University, Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 30:3109-18. 2012
    ..To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures...
  4. pmc BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Sebastian Schwind
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 116:5660-9. 2010
    ....
  5. pmc Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 116:788-92. 2010
    ..Our results indicate that WT1mut CN-AML represents a distinct entity with poor treatment response across age groups. This study has been registered at www.clinicaltrials.gov as #NCT00900224...
  6. pmc Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:5078-87. 2008
    ....
  7. ncbi request reprint High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3337-43. 2007
    ..To validate ERG overexpression as an adverse predictor and assess its prognostic value in the context of other molecular markers in cytogenetically normal (CN) -acute myeloid leukemia (AML)...
  8. doi request reprint MicroRNA expression in cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 358:1919-28. 2008
    ..A role of microRNAs in cancer has recently been recognized. However, little is known about the role of microRNAs in acute myeloid leukemia (AML)...
  9. pmc IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:2348-55. 2010
    ....
  10. pmc Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:4595-602. 2008
    ....
  11. pmc Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:596-604. 2010
    ....
  12. pmc TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
    Klaus H Metzeler
    The Ohio State University Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 29:1373-81. 2011
    ....
  13. pmc FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Susan P Whitman
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 116:3622-6. 2010
    ..FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene- and microRNA-expression signatures that provide biologic insights for novel therapeutic approaches...
  14. pmc Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Christian Langer
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Suite A434 Starling Loving Hall, 320 W 10th Avenue, Columbus, OH 43210, USA
    J Clin Oncol 27:3198-204. 2009
    ..CONCLUSION MN1 expression independently predicts outcome in CN-AML patients. The MN1 gene- and microRNA-expression signatures suggest biologic features that could be exploited as therapeutic targets...
  15. pmc Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Haematologica 96:1488-95. 2011
    ..To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia...
  16. pmc ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
    Klaus H Metzeler
    Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
    Blood 118:6920-9. 2011
    ..This first study of ASXL1 mutations in primary CN-AML demonstrates that ASXL1-mutated older patients, particularly within the ELN Favorable group, have unfavorable outcomes and may be candidates for experimental treatment approaches...
  17. pmc Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study
    Michael D Radmacher
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Suite A455 Starling Loving Hall, 320 West Tenth Ave, Columbus, OH 43210, USA
    Blood 108:1677-83. 2006
    ..Our analysis confirms the applicability of the gene-expression profiling strategy for outcome prediction in cytogenetically normal AML...
  18. pmc Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
    Guido Marcucci
    The Ohio State University, Comprehensive Cancer Center, Biomedical Research Tower 460 W 12th Ave, Columbus, OH 43210, USA
    J Clin Oncol 31:2086-93. 2013
    ....
  19. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
  20. pmc miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
    Ann Kathrin Eisfeld
    The Ohio State University Comprehensive Cancer Center, 300 West 10th Ave, Columbus, OH 43210, USA
    Blood 120:249-58. 2012
    ..The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications...
  21. pmc Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
    Sebastian Schwind
    Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 118:4188-98. 2011
    ..We conclude that low MN1 expression confers better prognosis in older CN-AML patients and may refine the European LeukemiaNet classification. Biologic features associated with MN1 expression may help identify new treatment targets...
  22. ncbi request reprint Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA
    J Clin Oncol 23:9234-42. 2005
    ..To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML)...
  23. pmc The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele
    Adrienne M Dorrance
    Department of Internal Medicine, Division of Hematology and Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, USA
    Blood 112:2508-11. 2008
    ..The differences between these 2 genotypes suggest that in select tissues the Mll-PTD requires cooperation with the Mll-WT in the genesis of the observed abnormality...
  24. pmc DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication
    Susan P Whitman
    Comprehensive Cancer Center, The Ohio State University, Columbus, USA
    Blood 112:2013-6. 2008
    ..Within the majority of MLL-PTD AML is a mechanism in which DNA hypermethylation silences a TSG that, together with MLL-PTD, can contribute further to aberrant chromatin remodeling and altered gene expression...
  25. pmc The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
    Susan P Whitman
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 106:345-52. 2005
    ....
  26. pmc Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia
    Krzysztof Mrozek
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210 1228, USA
    J Clin Oncol 30:4515-23. 2012
    ..To evaluate the prognostic significance of the international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML)...
  27. pmc Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
    Christopher J Hickey
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 121:159-69. 2013
    ....
  28. pmc Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 30:742-50. 2012
    ....
  29. pmc Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 17:333-47. 2010
    ....
  30. pmc Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Sebastian Schwind
    The Ohio State University, Comprehensive Cancer Center, Biomedical Research Tower, 460 W 12th Ave, Columbus, OH 43210, USA
    J Clin Oncol 28:5257-64. 2010
    ....
  31. pmc Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
    Krzysztof Mrozek
    Department of Internal Medicine, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, Room 1248B, The Ohio State University, 300 West Tenth Ave, Columbus, OH 43210 1228, USA
    Blood 109:431-48. 2007
    ..In this report, we review prognostic genetic findings in karyotypically normal AML and discuss their clinical implications...
  32. pmc Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations
    Adrienne M Dorrance
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio 43220, USA
    J Clin Invest 116:2707-16. 2006
    ....
  33. doi request reprint Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia
    Björn Hackanson
    Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, College of Pharmacy, Ohio State University, Columbus, Ohio, USA
    Cancer Res 68:3142-51. 2008
    ..Our results indicate that epigenetic alterations of C/EBP alpha are a frequent event in AML and that epigenetic treatment can result in down-regulation of a key hematopoietic transcription factor...
  34. pmc Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
    Il Kyoo Park
    Department of Microbiology, Virology, Immunology, and Medical Genetics, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA
    Blood 121:2064-73. 2013
    ..This also suggests that Axl should be pursued as a potential target for the treatment of FLT3-ITD(+) AML...
  35. pmc Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia
    Pearlly Yan
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 460 W 12th Ave, Columbus, OH 43210, USA
    Blood 120:2466-74. 2012
    ..Decitabine-related methylation changes were concordant with those previously reported in distinct genes. In summary, our study supports the feasibility of methylome analyses as a pharmacodynamic endpoint for hypomethylating therapies...
  36. pmc Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease
    Kelsie M Bernot
    The Ohio State University Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
    Blood 122:3778-83. 2013
    ..Taken together, these data support that liposomal bortezomib, as a single agent, eradicates Mll(PTD/wt):Flt3(ITD/wt) AML in mouse and may represent a powerful and potentially curative approach to high-risk human disease. ..
  37. ncbi request reprint BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
    Claudia D Baldus
    The Ohio State University, Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    Blood 102:1613-8. 2003
    ..7, 2.6, and 2.2. We conclude that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML with normal cytogenetics...
  38. pmc Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia
    Michael A Caligiuri
    Integrated Biomeducal Graduate Program, Comprehensive Cancer Center, Ohio State University, Columbus, OH 23240, USA
    Blood 110:1022-4. 2007
    ..Short-interfering RNA knockdown of mutant c-CBL present in MOLM-13 cells was growth inhibitory. In summary, novel mutations in c-CBL and CBL-b have been identified in human AML and may represent potential targets for novel therapeutics...
  39. pmc Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias
    Nicholas A Zorko
    College of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 120:1130-6. 2012
    ..Here we demonstrate, for the first time, that Mll-PTD contributes to leukemogenesis as a gain-of-function mutation and describe a novel murine model closely recapitulating human AML...
  40. pmc Dose escalation of lenalidomide in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 28:4919-25. 2010
    ..Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia...
  41. ncbi request reprint Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
    Shujun Liu
    Divisions of Hematology Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Cancer Res 65:1277-84. 2005
    ..These results suggest a novel mechanism for gene silencing mediated by RUNX1/MTG8 and support the combination of HDAC and DNMT inhibitors as a novel therapeutic approach for t(8;21) AML...
  42. ncbi request reprint SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients
    Kenneth D Swanson
    Cancer Biology Program, Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts, USA
    Genes Chromosomes Cancer 47:253-9. 2008
    ..Our findings suggest that SOS1 is not a significant human oncogene in most cancers. Furthermore, NS patients with SOS1 mutations may not be at increased risk of developing cancer...

Research Grants1

  1. FLT3 GENOTYPES IN ACUTE MYELOID LEUKEMIA
    Susan Whitman; Fiscal Year: 2006
    ..abstract_text> ..